RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort.
Emilia ScalzulliClaudia IeloCristina LuisePaolo MusiuMaria L BisegnaIda CarmosinoGiovanni Manfredi AssantoMaurizio MartelliMassimo BrecciaPublished in: Blood advances (2022)